
Your Feed
High Response Rates With T Cell Engagers in Follicular Lymphoma | Ryan Jacobs, MD | EHA 2024
CAR-T Therapy in Patients 75+ with Relapsed/Refractory DLBCL | Pierre Bories, MD, PhD | EHA 2024
Outcomes in High-Risk Subgroups After Ibrutinib and Venetoclax for CLL | Ryan Jacobs, MD | EHA 2024
Phase 1b-2 Dose Escalation Study Sonrotoclax + Dexamethasone | Binod Dhakal, MD | EHA 2024
CARTITUDE-4 Subgroup Analysis of Functional High-Risk Patients | Luciano Costa, MD | EHA 2024
Mezigdomide, Tazemetostat, and Dex in RRMM: Results from CA057-003 Trial | Luciano Costa, MD | EHA 2024
MAJESTIC-1 Study - A Subgroup Analysis of High-risk Patients | Luciano Costa, MD | EHA2024
ASCO/EHA Myeloma Updates 2024 | Claudio Cerchione, MD | EHA 2024
The Role of Combination FDG PET Plus Whole Body MRI for Staging | Claudio Cerchione, MD | EHA 2024










